Damora Therapeutics (DMRA) Retained Earnings (2019 - 2026)
Damora Therapeutics (DMRA) posted Retained Earnings of $893.5 million for Q1 2026, up 111314.21% on a QoQ basis from $802000.0 in Q4 2025, and up 419.06% year-over-year from $172.1 million in Q1 2025.
Damora Therapeutics (DMRA) Retained Earnings (2019 - 2026) Analysis & Trends
Damora Therapeutics' Retained Earnings history runs 8 years deep, the most recent figure standing at $893.5 million for Q1 2026.
- Quarterly Retained Earnings rose 419.06% year-over-year to $893.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $893.5 million (up 419.06% YoY) and the FY2025 annual result came in at $802000.0, up 726.8% from the prior year.
- Retained Earnings was $893.5 million for Q1 2026 at Damora Therapeutics, up from $802000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $893.5 million in Q1 2026 and bottomed at -$280.1 million in Q1 2025.
- A 5-year average of $35.0 million and a median of $97000.0 in 2024 frame the typical range for Retained Earnings.
- Peak annual rise in Retained Earnings reached 211991.24% in 2024, while the deepest fall reached 205884.25% in 2024.
- Damora Therapeutics' Retained Earnings stood at -$217.7 million in 2022, then fell by 17.61% to -$256.1 million in 2023, then jumped by 100.04% to $97000.0 in 2024, then jumped by 726.8% to $802000.0 in 2025, then jumped by 111314.21% to $893.5 million in 2026.
- Business Quant data shows DMRA's Retained Earnings at $893.5 million in Q1 2026, $802000.0 in Q4 2025, and $823000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -622,000.00 |
| 10 | Damora Therapeutics | 1.01 Bn | 807.71 Mn | - | 893.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 893.54 Mn |
| Dec 31, 2025 | 802,000.00 |
| Sep 30, 2025 | 823,000.00 |
| Jun 30, 2025 | 292.30 Mn |
| Mar 31, 2025 | -280.06 Mn |
| Dec 31, 2024 | 97,000.00 |
| Sep 30, 2024 | 665,000.00 |
| Jun 30, 2024 | 290.29 Mn |
| Mar 31, 2024 | -261.60 Mn |
| Dec 31, 2023 | -256.09 Mn |
| Sep 30, 2023 | -249.60 Mn |
| Jun 30, 2023 | -137,000.00 |
| Mar 31, 2023 | -127,000.00 |
| Dec 31, 2022 | -217.74 Mn |
| Sep 30, 2022 | 278.32 Mn |
| Jun 30, 2022 | 276.50 Mn |
| Mar 31, 2022 | -173.05 Mn |
| Dec 31, 2021 | -320,000.00 |
| Sep 30, 2021 | -142.70 Mn |
| Jun 30, 2021 | 271.19 Mn |